Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

INTRODUCTION: The selective estrogen receptor degrader fulvestrant is approved for the first-line treatment of postmenopausal patients with hormone receptor-positive (HR+), locally advanced or metastatic breast cancer who have not received prior endocrine therapy. We evaluated the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Telford, Claire, Bertranou, Evelina, Large, Samuel, Phelps, Hilary, Ekman, Mattias, Livings, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861400/
https://www.ncbi.nlm.nih.gov/pubmed/31025302
http://dx.doi.org/10.1007/s41669-019-0134-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861400/
https://www.ncbi.nlm.nih.gov/pubmed/31025302
http://dx.doi.org/10.1007/s41669-019-0134-3

Ejemplares similares